MedTrace Logo

Cell Bound Complement Activation Proteins as Markers of Liver Injury

NCT01025531 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2014-12-08

No results posted yet for this study

Summary

Subjects who eventually undergo treatment for HCV, we will gather treatment data (start and stop dates), and repeat CB-CAP analysis at weeks 4, 12, 24 and 72 (+/- 2 week window allowed at each time point) to determine whether CB-CAPs levels predict virologic response in treated subjects. Routine laboratory data will also be collected at these time points.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Adeel Butt, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025531 on ClinicalTrials.gov